Cite
HARVARD Citation
Chawla, M. et al. (2022). IDF21-0453 Phase-3 active control trial to evaluate Safety and Efficacy of Repaglinide plus Voglibose combination in T2D patients. Diabetes research and clinical practice. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Chawla, M. et al. (2022). IDF21-0453 Phase-3 active control trial to evaluate Safety and Efficacy of Repaglinide plus Voglibose combination in T2D patients. Diabetes research and clinical practice. p. . [Online].